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Semi-Parametrics Dose Finding Methods
Matthieu Clertant and John O’Quigley

Abstract

We describe a new class of dose finding methods to be used in early phase clinical
trials. Under some added parametric conditions the class reduces to the family
of continual reassessment method (CRM) designs. Under some relaxation of the
underlying structure the method is equivalent to the CCD, mTPI or BOIN classes
of designs. These latter designs are non-parametric in nature whereas the CRM
class can be viewed as being strongly parametric. The proposed class is characterized as being semi-parametric since it corresponds to CRM with a nuisance
parameter. Performance is good, matching that of the CRM class and improving
on it in some cases. The structure allows theoretical questions to be more easily
investigated and to better understand how different classes of methods relate to
one another.

Semi-Parametric Dose Finding Methods
Clertant, M. and O'Quigley, J.

1

Université Pierre et Marie Curie, Paris, France

Abstract:

We describe a new class of dose nding methods to be used in early phase clinical

trials. Under some added parametric conditions the class reduces to the family of continual
reassessment method (CRM) designs. Under some relaxation of the underlying structure the
method is equivalent to the CCD, mTPI or BOIN classes of designs. These latter designs are
non-parametric in nature whereas the CRM class can be viewed as being strongly parametric.
The proposed class is characterized as being semi-parametric since it corresponds to CRM with
a nuisance parameter. Performance is good, matching that of the CRM class and improving
on it in some cases. The structure allows theoretical questions to be more easily investigated
and to better understand how dierent classes of methods relate to one another.
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Introduction
The importance of early phase dose nding studies - so called Phase I and Phase I/II clinical
trials - is dicult to overstate. This is particularly so in oncology where it is believed that
a signicant number of the more than ninety percent of failed large scale randomized clinical
trials can, to a more or lesser degree, be explained by an inecient or an inaccurate early
phase study. The recommended dose would have been either too high, and poorly tolerated,
or too low and, in consequence, unable to provide an adequate anti-tumour response.

It

is widely recognized by statisticians and clinicians alike that the standard 3+3 dose nding
design (Storer, 1989) widely employed in Phase I trials is fatally awed and, in some sense, not
t for purpose. As a result the last twenty ve years has seen considerable statistical research
into early phase designs that are more ecient while simultaneously paying attention to the
ethical constraints required in the running of any such trial.
Dierent approaches divide themselves into two classes; the rst - examples include the
3+3 and the Rolling Six (Skolnik et al., 2008) - are called algorithmic designs since no modeling
takes place and the escalation, de-escalation rules are determined solely as a function of some
set of the most recent observations. They have a Markov property, sometimes referred to in
this context as a lack-of-memory property. The second class of designs are called model-based
designs. Their motivation is to impose greater structure on the observations in order to increase
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the information obtained through sampling as well as to satisfy large sample convergence of
the recommended dose to the true MTD. Statistical properties such as almost sure convergence
are important in as much as, without such properties, it is dicult to feel condent in the
solidity of any approach. At the same time, in real studies, sample sizes are often no more than
20 to 30 and so it is also crucial to have desirable nite sample properties such as coherence
(Cheung, 2005).

Simulations, across broadly varying situations, have been a useful help in

developing methods.

One clear advantage of the model-based designs is their ability to be

generalized to deal with more complex situations such as group heterogeneity, combination
therapies and toxicity attribution error.
The most well known of the model-based designs is the continual reassessment method
(CRM) introduced by O'Quigley, Pepe and Fisher (1990). The method has been very successful
but despite its now well known superior performance over the standard design, its use still lags
behind that of the standard design. One explanation for this is that many clinicians are not at
ease in using a method whose in-trial operating behaviour can not be immediately anticipated
as well as the fact that help in the form of an able bodied statistician is recommended. But
there are other statistical concerns (Azriel et al., 2011) that have led to the development of
many competing model-based approaches. Among these are EWOC (Babb et al., 1998), mTPI
(Ji et al., 2010) and BOIN (Liu and Yuan, 2015). Some authors have pointed out that the
conditions for almost sure convergence in Shen and O'Quigley (1996) are very restrictive, and
therefore not realistic. Cheung and Chappell (2002) and Azriel (2012) described ways to relax
these assumptions but the concerns still remain.
The CRM is based on a strong parametrisation of the regression function, so much so
that it is often described as an under parametrized model. Taking our cue from Cheung and
Chappell's work on the CRM, we introduce a semi-parametric characterization of the method
(Section 2). This characterization can also be viewed as a hierarchical Bayesian model having
as a rst level the main parameter of interest, the MTD itself, and, on a secondary level, families
of dose-toxicity curves constrained only by the location of the MTD. Within this framework
we can characterize several other current methods.

We immediately gain some theoretical

advantages such as almost sure convergence to the Maximum Tolerated Dose (MTD) under
weaker conditions than those currently admitted.
sample behaviour in more general situations.

It is also much easier to anticipate large

The general structure allowed for by semi-

parametric models enables deeper study of the various methods currently available. Perhaps
no less importantly, we propose methods beneting from improved asymptotics properties,
computationally very fast, which, for small samples, obtain as good and sometimes better
results than the CRM. Cheung and Chappell's characterization for the MTD as an interval
rather than a point paved the way to more realistic and achievable goals for dose nding
studies. These ideas are fundamental to our development here and, within this context, we
describe two central features of asymptotic behaviour. The rst is that of being sensitive
and the second that of being balanced.

Under very wide and realistic dose-toxicity curves
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we show that the semi-parametric method exhibits desirable large sample behaviour regarding
these properties, and that this behaviour will indeed be reected in commonly observed nite
samples. For any given situation, the large sample behaviour of the semi-parametric method
can be characterized by either almost sure convergence to the MTD or by innite oscillation
over two adjacent levels, the rates of visitation to either one of these levels being quantied
according to Kullback-Leibler divergence.
A user friendly program in R is available at address https://github.com/MatthieuMC/
SPM_project_01 .

1

Context of model-based designs

1.1 Basic set-up and notation
The statistical purpose is to estimate the root of an unknown dose-toxicity regression function
as observations are accumulated sequentially. The observations are the sequences:
At step

n, the variable Xn

and the variable

Yn

is the dose selected from a range of available doses;

Xn = d

D = {1, . . . , m}

is the observed binary response at this dose taking values

a Dose Limiting Toxicity (DLT) and
is Bernoulli with parameter

0

βd ,

otherwise.

(Xn , Yn )n∈N .
{0, 1} : 1

The conditional distribution of

Yn

for

given

which implies that at each dose is associated a prob-

ability of toxicity independent of the way in which patients are selected into the study. The
range

D

has been chosen by clinical expertise so that the doses are ordered in terms of the

probability of toxic response.

Assumption 1.1.

∀n ∈ N, ∀d ∈ D, βd = P(Yn = 1|Xn = d)

with β1 < . . . < βm .

Estimating the root of the regression function enables us to determine which dose among
those available in the range

D

suggests itself as having a probability of toxicity the closest

to some maximum amount

α

chosen by the investigators.

∗
the MTD (maximum tolerated dose): d

This dose, noted

= arg inf d∈D |βd − α|.

d∗ ,

is called

As patients are included

sequentially into the study, we suppose that all of the information contained in the sample,

(X1n , Y1n ) = ((X1 , . . . , Xn ), (Y1 , . . . , Yn ))

is available to guide the selection of the dose

Xn+1 .

The ethical constraints of the study imposed by the clinical team encourages us to use all the
available information at each step in order to choose our best current estimate of the MTD as
the dose to be given to the following patient. The following denition (Cheung, 2005) describes
a property that any sensible design should have.

Denition 1.1. A method, M, is said to be coherent if the selection of the next dose given
the observed sample satises, for all d ∈ D and n ∈ N:
(Xn , Yn ) = (d, 0) ⇒ M(X1n , Y1n ) > d

and

(Xn , Yn ) = (d, 1) ⇒ M(X1n , Y1n ) 6 d ,

where M(X1n , Y1n ) denotes dose Xn+1 given (X1n , Y1n ).
3
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The following assumption restricts attention to design based estimates that are adapted
to the accummulating observations.

Assumption 1.2. The current estimator of the method satises:
where σ(X1n , Y1n ) is the sigma-algebra generated by the sample.

M(X1n , Y1n ) ∈ σ(X1n , Y1n ) ,

Under this condition we are able to obtain classical asymptotic properties for frequentist
estimators

βbd,n

dened by:

βbd,n =

n1d
n1d
=
,
nd
n0d + n1d

where

nid =

n
X

1{Xn =d,Yn =i} , i ∈ {0, 1} .

(1)

j=1

Lemma 1.1. For all methods satisfying Assumption1.2, we have:
(i) Law of large numbers: βbd,n n −→
βd , a.s.
→+∞
d

(ii) Law of the iterated logarithm: for all βd ∈]0, 1[, with σd =
√



nd βbd,n − βd
lim sup p
=1
nd →+∞ σd 2 log (log(nd ))

Proof.

p

βd (1 − βd ),

we have

√

and



nd βbd,n − βd
lim inf p
= −1 , a.s.
nd →+∞ σ
d 2 log (log(nd ))

Part (i) is shown in Azriel, Mandel, and Rinott (2011, lemma 3) and Part (ii) in the

supplementary material.

This very general result provides no useful method in itself. Indeed, the event
random depending on the vector

β = (βd )d∈D

{nd → +∞}

is

and the chosen method. It is not immediately

clear how to obtain a consistent estimator of the MTD because we do not wish for each dose
to be observed innitely often. A good dose nding method will be all the more desirable as
it fullls two criteria:
(1) (TR, treatment): we would like the greatest possible number of patients to be treated at
and close to the MTD during the study.
(2) (PCS, percentage of correct selection): the method should lead us with high probability
to a correct determination of the MTD.
Reconciling and jointly optimising these two criteria creates specic diculties for dose nding
studies. In this context it is worth recalling an impossibility theorem of Azriel et al. (2011)
that throws a useful light on the asymptotic results obtained here. These authors have shown
that no method exists that would, for all situations, allow the current estimator to be strongly
consistent.

Only particular congurations with respect to the employed method result in

strong consistency.
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Theorem 1.1. Let M be a method satisfying Assumption1.2. A scenario
sumption 1.1 exists such that:

β

satisfying As-

Pβ (∃N : ∀n > N, M(X1n , Y1n ) = d∗ ) < 1 .
Indeed, if the method recommends a single dose for

n large enough, observations on competing

doses will cease. The information we have at these doses is nished and, of course, we may
then make an incorrect recommendation however large

n.

Example 1.1. Let β = (0.05, 0.10, 0.20, 0.35, 0.55, 0.7) and α = 0.2 . Suppose that, for n
large enough, the design selects only dose 2 and the results for dose 3 are 2 DLT among 5
observations: βb3,n = 0.4. In such circumstances, for all dose d 6= 2, the law of large numbers
will not apply to βbd,n because the dose d is not innitely tested. The inaccuracy in the estimate
of toxicity related to dose 3 will not be overcome by increasing sample size. However, note that
the event {n2 → +∞} together with the assumption of monotonicity 1.1 allow us to eliminate
almost surely dose 1 from the candidate doses for being the MTD.
According to the Assumption 1.1, the two doses associated with toxic probabilities either
side of the target dose

α

are consecutive. It would then appear desirable as a large sample

property to concentrate experimentation on these doses. The class of methods introduced in
this article arise in a natural way from a critical analysis of the asymptotic properties of the
CRM (O'Quigley et al., 1990). This very general construct would allow us to include a wide
range of, at rst glance, diverse methods under a single general heading. This generalization
opens the way to make progress on two fronts; that of critical evaluation of the overall strategy
and that of more ecient parameterization of particular existing methods alongside their
extensions when dealing with more complex clinical situations. In the rest of the article, we
study this in relation to the CRM. The proposed parametrisation enables us to reproduce
the global behavior of this method while obtaining better theoretical properties and allows
us to escape those diculties consequent on poor model specication (skeleton). In further
unpublished work we study more deeply this generalization as it relates to the CCD (Ivanova
et al., 2007), mTPI (Ji et al., 2010) and BOIN methods (Liu and Yuan, 2015), since the
semi-parametric structure leads to immediate improvements in all of these designs.

1.2 Parametric methods: Continual Reassesment Method
In this paragraph, we recall the principle features of the continual reassessment method. We
do this in a particular way which helps us to see how the new developments presented here
sit quite naturally within the basic framework of the CRM. The CRM method works by
approximating the dose-toxicity relationship
parameter

d 7→ βd

by a family of continuous functions of a

a.
f : X × [A, B] → [0, 1]
7→ f (x|a) ,

(x, a)
5

Hosted by The Berkeley Electronic Press

with

[A, B]

a nite interval and

the family of functions
Note that

f (x|a)

X

a continuous set containing the range of doses

(f (.|a))a∈[A,B]

the model and the vector

probability of toxicity at dose

x

under parameter

a.

general working of CRM. In the Bayesian setting,
its posterior given the observations

Qn

i=1 f (Xi

|a)Yi (1

x,

is the toxicity associated with the dose

− f (Xi

|a))1−Yi

β

D.

We call

the scenario (or reality).

that is to say a model for the

The following algorithm describes the

G

is the prior distribution of

(X1n , Y1n ) : Gn (da) ∝ Ln (a) × G(da),

a

where

and

Gn

Ln (a) =

.

Step 1. Through the likelihood Ln , the current amount of information
update our estimate an of the parameter a or its posterior Gn .

(X1n , Y1n )

is used to

Step 2. The estimator of the next dose, Xn+1 is obtained as a function of an or Gn .
Many possibilities are available for the second step.
estimators of toxicity at each dose

One approach is to calculate the

d ∈ D : β̃d,n = f (d|an )

or

β̃d,n = EGn [f (d, a)].

The

next dose is then the one whose estimated probability of toxicity is the closest to the desired
target:

:

Xn+1 = arg mind∈D |β̃d,n − α| .

In order to set the context for the general semi-

parametric model, we propose a new estimator for step 2 which is based on the analysis
of Cheung and Chappell (2002). These authors provided an interpretation and insight into
poor model specication by breaking down the parameter space:

Hd = {a ∈ [A, B] : |f (d|a) − α| < |f (d0 |a) − α|, ∀d0 6= d} .
on which the model recommends dose

d

The set

[A, B] = ∪d∈D Hd ,

Hd

with

is the parametric space

as the MTD. Asymptotic concerns together with the

sequential nature of CRM and the partition of the parameter space leads to the following
assumption. Let

ad

Assumption 1.3.

be such that:

ad∗ ∈ Hd∗

Assuming that the functions

f (d|ad ) = βd .

and ∀d ∈ D \ {d∗ } , ad ∈/ Hd .
f (.|a)

are increasing for all

a,

Assumption 1.3 is equivalent to

the one under which Azriel (2012) shows the strong consistency of CRM. Theorem 1.1 rules
out the existence of a method providing almost sure convergence to the MTD regardless of the
circumstances. Indeed, Assumption 1.3 can not be checked because it requires control over the
reality expressing itself via the parametric elements

ad

(Cheung and Chappell, 2002, Figure

1) (Section 2.2, Figure 1). However, it does throw light on how the method works: the goal is
to identify the MTD among a small range of doses
estimation of a parameter in an innite set

D,

at the same time the CRM leans on the

[A, B]. The method tries to ascertain the belonging

of this parameter to one of the sets of the family

(Hd )d∈D .

On the basis of this analysis, we

propose the following Bayesian estimator for the next dose (step 2) of CRM:

Xn+1 = arg max Gn (Hd ) .

(2)

d∈D
The parametrization of the CRM can be expressed in terms of the MTD,
a distribution on the range of doses such that for all

θ ∈ D,

we have:

θ.

The prior

Π(θ) = G(Hθ ).

Π

is

The

6

http://biostats.bepress.com/cobra/art116

family of priors

Λ = (Λθ )θ∈D

This means that

Λθ

probability measure

is the distribution

Λ⊗Π

Λθ (.) = G(.|Hθ ).

describe the dose-toxicity curve and we set

G

Hθ .

on the set

and the posterior

Πn ,

The prior

G

is then equal to the

following the observations

(X1n , Y1n )

easily obtained by integrating the parameter of the dose-response curve for each

R

can be

θ : Πn (θ) ∝


Ln (a)Λ(da|θ) Π(θ) .
This hierarchical model being strictly equivalent to the Bayesian CRM, has no particular

value in this form.
butions

Λ(.|θ)

It does though allow a greater conceptual understanding of the distri-

and their topological supports.

Relaxing the structure of these distributions

and adding some exibility amounts to a model involving a nuisance parameter. This semiparametric setting provides methods that benet from improved asymptotic properties while
still conserving operating caracteristics for small sample size that are similar and in some cases
better to those of the CRM.

2

Semi-Parametric Models

2.1 General semi-parametric structure
Semi-parametric models (SPM) take as their starting point the direct modelling of the MTD
itself. This is formalized within the framework of Bayesian hierarchical models. It can also be
viewed in terms of model selection based on bayes factors. The hierarchical posterior allows us
to compare and evaluate

m classes indexed by the main parameter of interest, the MTD. These

classes are structured by a prior referred to as a prior model (see Section 2.2).

The initial

topological support of the prior is a broad one, corresponding to a non-informative situation.
We model the accumulating information via an
we introduce

F

an

m-dimensional

range of situations. Let
dose
us

m

j.

The set

F

m-tuple

of Bernoulli laws.

To this end

vector space of Bernoulli parameters covering a very wide

q = (q1 , . . . , qm ) ∈ F

, and

qj

the specic parameter corresponding to

is partitioned in terms of the main parameter of interest,

θ,

which provides

distinct classes, each individual class containing an innite set of members sharing the

same MTD:

F =

S

Fθ ,

with

θ∈D

Fθ = {q ∈ F : ∀j ∈ D , |qθ − α| 6 |qj − α| , j < θ ⇒ qj < α , j > θ ⇒ qj > α} .
Given that

θ

takes on the value of some particular dose-level, then

toxicity curves having
toxicity less than
vector

Fθ

α,

(f (d, a))d∈D ,

θ

as the MTD. Lower levels in

Fθ

and conversely for higher levels.
with

a ∈ Hθ

Fθ

is the collection of dose-

will necessarily have probabilities of

For all

β

in

Fθ ,

the MTD is

(see the preceding section), is then included in

can be seen as a general extension of

Hθ ,

such that

F

(3)

Fθ .

θ.

The

Indeed,

contains all the probability measure

in compliance with Assumption 1.1. From our point of view, determining the MTD

θ

can be

summarized by the following question. Which class is the most plausible one to have generated

7
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the data? The likelihood is:

Ln (q) =
where

n1j

Y
16i6n

is the number of toxicities at dose

treated at dose

j.

The set

F

j

and

n1

Y

(qXi )Yi (1 − qXi )1−Yi =

16j6m

0

qj j (1 − qj )nj ,

nj = n1j + n0j

is the number of patients

is endowed with a probability measure

Λ(.|θ) = Λθ (.)

Λ⊗Π

measure on

D

and the support of the measure

means that

Π

is a vector of m non-negative numbers summing up to

distribution

(Λθ )θ∈D

indexed by the potential MTD,

θ.

such that

is included in the class

1

and

Λ

Π

Fθ .

is a

This

is a family of

The posterior distribution of

θ

given

(X1n , Y1n ) is:


Z Y
m
1
0
n
Πn (θ) = Π(θ|X1n , Y1n ) ∝ 
qj j (1 − qj )nj Λθ (dq) Π(θ) .

(4)

j=1
When we focus on the class

Q

n1j
16j6m qj (1

n0j

Fθ ,

− qj ) Λθ (dq) .

Λθ

given

(X1n , Y1n )

Λθ,n (dq) ∝

is:

By replacing this result in (4), we have:

Z
Πn (θ) ∝

the posterior distribution of

Yn
qX
(1
n

− q Xn )

1−Yn


Λθ,n−1 (dq) Πn−1 (θ) .

(5)

Thus, each new observation leads rst to an update concerning the distribution
according to the expected value of the likelihood with respect to

q conditioned by θ.
Λθ

step, this observation is used to update the probability measures
formula. In the following section, the family

(Λθ )θ∈D

Π by weighting
In a second

on classes using Bayes

will be called the prior model because

of the predictive model-like role it plays in sequential decision making. Fitting the model is
carried out by updating the prior
at dose

j, β̃j ,

Λθ .

Finally, estimators of the MTD,

θb and

of the toxicities

arise naturally and are the same we have already proposed and described for the

CRM:

θbn = arg max Πn (θ) , β̃j = E(Λ⊗Π)n [qj ] =
θ∈D

m Z
X


qj Λθ,n (dqj ) Πn (θ) .

(6)

θ=1

The general method might be summarized by the following points:
1. The current sample of observations
2. The estimator of the next dose is

(X1n , Y1n )

is used to update the posterior

Πn .

Xn+1 = θbn .

We introduce this semi-parametric class of models in the most usual situation of a Phase study
I summarized by Assumption 1.1.

Under this assumption, a phase I study only deals with

a nite dimensional parameter. The term 'semi-parametric' refers to the methodology used
to build this structure.

With the goal of determining the parameter of interest, the MTD,

a parametric model is extended by using nuisance parameters:

when the MTD is dose

3,

8
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we do not have to estimate precisely

q1

or

q5 .

The proposed model covers the whole range of

scenarios, "which consists of all probability measures on the sample space for the observations"
(Bickel et al., 2005), as a non-parametric model does. The gain of exibility does not result in
a loss of simplicity. As all the parameters are readily available, the semi-parametric class of
models can be easily calibrated to reproduce the behavior of almost all of the designs currently
in use, including the algorithmic designs. This broad generalization allows us to investigate
theoretical questions, to more readily allow comparison between competing designs and to
look for ways to improve on any given design. Finally, the simplicity of calibration (see below)
together with the great range of possibilities suggest that the semi-parametric class of models
might be extended to more complicated situations in phase I involving innite dimensional
parameters: known examples being continuous grade of toxicities, heterogeneous populations,
combination studies and time-to-event toxicities.

2.2 A simple prior model specication
A general calibration of SPM can be obtained as follows. We focus on the prior distributions
inside the classes,

(Λθ )θ∈D .

The support

Sθ

of the distribution

will reect locally the ordering of the parameters

βj

Λθ

will be included in

Fθ

and

(Assumption 1.1). This local property

is sucient to ensure that the design behaves in a sensible way.

Indeed, after each new

observation or set of observations, the practitioner would like the method to indicate if the
dose appears too high, too low or acceptable.
interval

For this purpose, a natural partition of the

[0, 1] into 3 sets is introduced: I = [α − , α + ], A = [α + , 1] and B = [0, α − ].

support of distributions that we choose are in

m

The

dimension as the whole space of probability

measures for the observations. They are dened according to the constraints on the MTD.
The Bernoulli parameters at each dose are considered as independent from the point of view
of a single class

θ.

Assumption 2.1. (i) The support Sθj of the marginal Λjθ satises: Sθj = B when j < θ,
Sθj = I when j = θ and Sθj = A when j > θ. We then have: Sθ = Sθ1 × . . . × Sθm ⊂ Fθ . (i) Λθ is
a product of unidimensionnal distributions at each doses: Λθ (dq) = Λ1θ (dq1 ) × . . . × Λm
θ (dqm ) .
The point (i) of the above assumption means that the support of

j

qj

depends on whether

is above, below, or at the level of the MTD. In each circumstance the support reects the

constraints on

qj .

The point (ii) is an independence assumption given

θ.

This independence

assumption could be relaxed although we have not studied this. Choosing the width of the
central interval is an important step in the parametrisation as it determines consistency (see
section 3). We propose here to use an interval centered in

α.

This leads the method to mimic

the CRM under the most common scenarios. Non-centered intervals can also be used which
provide more or less conservative results.
The direct calibration of the supports

Sθ

allows us to avoid those cases described in (Shen

and O'Quigley, 1996) that can result in non-convergence (see Figure 1 and scenario 8 in

9

Hosted by The Berkeley Electronic Press

0.8
0.6

0.8
0.6

H3

S3

0.4
0.2

0.4

Toxicity

H1

0.2

Toxicity

H2

H5

0.0

0.0

H4

1

2

3

4

5

1

2

3
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(a) CRM, G(.|H3 ) (see section 1.2)

(b) SPM, Λ3

Figure 1: Support of the dose-response curves for distributions

G(.|H3 )

and

Λ3 .

The broken

lines represent two kinds of poor specication for CRM, the atter curve fails Assumption 1.3.

Table 3) as well as poor performance consequent upon poor model specication (a slope in
the neighborhood of the MTD, Figure 1 and scenario 5 and 6 in Table 3).
independance of parameters

qj 's

in Assumption 2.1 is only valid conditionally given

means that all the information about dependence is captured by
main goal of the study: determining the MTD,
that the supports

Sθ

Note that the

θ.

θ.

This

θ and is used to accomplish the

Thus, the independance in the class implies

include locally decreasing scenarios of the dose-response phenomenom,

but all the scenarios in that class respect the mononicity between
Figure 2 (b) illustrates the dependence between the parameters
sub-models that include monotonicity restrictions.

qj 's

θ

and the other doses.

and how we can describe

In this way, the family

(Λθ )θ∈D

can be

built from the model of CRM. As it is used to make inference in place of the usual parametric
is called the prior model.

0.6
0.4

Toxicity

0.0

0.2

0.4
0.2
0.0

Toxicity

0.6

0.8

(Λθ )θ∈D

0.8

model, the family

1

2

3

4

5

1

Doses

2

3

4

5

Doses

(a) Regression curves of CRM, modes for SPM

(b) Sample under Λ2 and Λ3

Figure 2: Prior model built on the CRM model
The Beta distribution linked to the likelihood has a key role as it allows us to use conjugate
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B(a + 1, b + 1)

priors.

to interval

I

and

BI (a + 1, b + 1)

with shape parameters

a+1

R2+

denote the Beta distribution and its restriction
and

b + 1.

g

Let

be the following function:

g :

xa (1

[0, 1] ×
→ [0, 1] , with g(x, a, b) =
− x)b . The density function of B(a + 1, b + 1)
R1
is g(., a, b)/B(a + 1, b + 1), with B(a + 1, b + 1) =
0 g(x, a, b)dx. When conjugate priors
θ
are used, the whole prior model can be summarized by a triplet [, (q )θ∈D , c]. The number 
θ
m are the modes
belongs to [0, 1] and determines the centered interval. The vectors q ∈ [0, 1]
of distributions

Λθ .

The positive real value

c

is the dispersion parameter of the distributions.

Uniform priors on the topological supports are updated so that,

Λθ ≈

θ−1
Y

m
Y

BB (cqjθ +1, c(1−qjθ )+1)×BI (cqθθ +1, c(1−qθθ )+1)×

j=1

BA (cqjθ +1, c(1−qjθ )+1)

(7)

j=θ+1

In Figure 2 (b), the prior model is built by using a model

f (d, αθ ) = α

(see Figure 2 (a)).

f

of CRM:

q θ = [f (j, |αθ )]j∈D ,

with

All the parametrisations proposed in this article fulll an

assumption about stochastic ordering on the prior model. At each moment of the trial, for
any dose

θ

j0 ,

the marginal posterior

0
Λjθ,n
(.)

should be stochastically greater than

Λjθ00 ,n (.)

when

0
is smaller than θ (see supplementary material, Section 2). In the setting of SPM, it is the

main argument needed to obtain the coherence property of Cheung (2005). The prior model
should respect a local order between the classes corresponding to the dierent MTD, and not
inside one class.

Theorem 2.1. If the prior model satises 2.1 and the assumption about stochastical ordering
(supplementary material), then SPM is coherent (Denition 1.1).
This analysis throws a light on the natural similarities between the prior model and parametric
models which satisfy the monotonicity assumption.

2.3 Summary and illustration
We have
at dose

q = (q1 , . . . , qm ) a possible dose-toxicity scenario,

j. Λ = (Λθ )θ∈D

MTD. Given the MTD,
to be at dose

is a family of priors for

θ, Λθ

q,

i.e.,

indexed by

qj

θ,

is made up of only those vectors

q

is the probability of toxicity

the parameter identifying the
for which we know the MTD

θ. Π is the prior on the parameter θ, often a discrete uniform.

The couple

(Π, Λ)

then describes a hierarchical model where the rst level deals with the goal of the study, the
MTD itself, and the second level concerns the dose-response curve. Bayes formula is used for
obtaining the posterior

Πn

according to the data already observed (see Section 2.1, Equation

4). The next selected dose is chosen to be the most probable:
prior model

(Λθ )θ∈D

Xn+1 = arg maxθ∈D Πn (θ). The

can be calibrated in such a way to avoid those diculties that arise for the

parametric model as a result of misspecication. Given

θ,

we assume independence between

the dierent probabilities of toxicity, which means that each prior

j
his marginals Λθ on each dose

j

Λθ

is the simple product of

(Section 2.2). Under this assumption, the next dose selected

11
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corresponds to the parameter
doses weighted by the prior

θ

that maximizes the product of the expected likelihood at each

Π(θ) :


Xn+1 = arg max Πn (θ) = arg max 
θ∈D

θ∈D

m Z
Y


Ln (qj )Λjθ (dqj ) Π(θ)

(8)

j=1

Our approach is based on the following two steps:
-

Calibration of Λ:

(a) A partition of the probability space of toxicities is used for

calibrating the marginal laws:

B = [0, α − ], I = [α − , α + ]

(b) The marginals are chosen from the Beta family (conjugacy).
of the marginal

Λjθ

following rules: if

j < θ,

Calibration of Π:

A = [α + , 1].

(c) The support

Sθj

is restricted to one of the three preceding intervals according to the

has support limited to
-

and

I

the marginal has support limited to
and if

j > θ,

B,

if

j = θ,

the marginal

the marginal has support limited to

A.

This prior is a vector of probabilities on the range of doses. It can be

easily calibrated. When the clinician has no extra-information to provide on the location
of the MTD, a non-informative prior might be chosen, a discrete uniform being a natural
candidate. However, given that this prior will drive the early escalation behavior until
we encounter a DLT, it is appealing to note that, not only will this prior impact early
behavior but, we can calibrate the prior in such a way as to obtain the very behavior
we would like to see.

Early escalation can be slowed down or speeded up by simple

calibration of this prior.
The following examples are based on a very simple parametrisation.

The target is xed at

α = 0.2.

SPM (0.05,0,0,0): The value  is 0.05 such that I = [0.15, 0.25]. All the marginals are
uniform on their respective interval. The distribution Π is uniform on the range of doses.
SPM(0, 1/10, 1/3, 40) : The size of the centered interval is null: Λθθ is a constant random
variable in α, for all θ ∈ D. We set: j < θ ⇒ qθj = 1/10, j > θ ⇒ qjθ = 1/3 and c is equal to
40 (See Equation (7)). The distribution Π is uniform.
In Table 4, the overall performances are summarized.

When escalating, skipping a dose is

not allowed as this is now a requirement in these kinds of designs. These designs are computationally very fast.

R codes are available from the authors on request or at address:

https://github.com/MatthieuMC/SPM_project_01.

3

Large sample theory

The interval

I is centered on α: I = [α−; α+].

All of the results presented here remain valid

for a non symmetric interval. Theorem 1.1 states that if treatment in a sequential experiment
is determined by the current estimator of the MTD, then this estimator cannot be strongly
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consistent. However, setting

α

with accuracy

,

 > 0,

if we assume that one or more doses are close enough to

then we shall obtain almost sure convergence of the design to this set of

doses. Conversely, if we assume that neither dose is close enough to the threshold, the current
estimator shall recommend alternatively the two doses with toxicities directly located on both
sides of

α.

We introduce the following technical assumption which leans on the regularity of

the prior model.

Assumption 3.1. Let Sθ and Sθj be the topological support of Λθ and Λjθ . The following
conditions are valid except when Λθθ is a Dirac measure.
(a) For all j ∈ D, the marginal distribution Λjθ is absolutely continuous with respect to
Lebesgue measure and λjθ denotes its density function.
(b) There exist two numbers s and S in (0, ∞), such that, for all (j, θ) ∈ D2 , we have:
∀ qj ∈ Sθj , s < λjθ (qj ) < S .
When the density function can not be bound into the neighborhoods of

0

or

1,

we can obtain

compliance with the preceding assumption by using uniform priors on the small intervals
and

[0, δ[

]1 − δ, 1]:
λjθ (qj )

Z
∝

δ

g(q, cqjθ , c(1 − qjθ ))dq 1[0,δ[ (qj ) + g(qj , cqjθ , c(1 − qjθ )) 1[δ,α[ (qj ).

0

Moreover, from the point of view of proving consistency, this assumption deals only with
theoretical scenarios where there exist some doses which are never toxic and others which
are always toxic. The following two denitions characterize the asymptotic behavior of SPM:

-sensitivity

is a property connected to indierence intervals. (Cheung and Chappell, 2002).

Denition 3.1. Let  > 0 et I = [α − ; α + ]. We consider the collection of doses associated
with a toxicity belonging to I : E(I , β) = {j ∈ D : βj ∈ I } . A method, M, is called sensitive, if for all β such that E(I , β) 6= ∅, we have:
Pβ [∃N , ∀n > N : M(X1n , Y1n ) ∈ E(I , β)] = 1 .
If the true situation is such that a unique dose is associated with a target in the interval
then a method that is
target located within

-sensitive

I ,

I ,

converges almost surely to the MTD. When no dose has a

the SPM will assume an oscillating behavior between two doses with

toxicities either side of the target

α.

Denition 3.2. The letter D̃ denotes the set of doses innitely observed:
D̃ = {j ∈ D : nj

→

n→+∞

+∞} .

Let b (below) and a (above) be the two consecutive doses associated to toxicities either side of
13
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the target α. A method, M, is called -balanced, if for all β such that E(I , β) = ∅, we have:
D̃ = {a, b} , a.s.
We might view oscillation as a desirable property for designs whose aim is to locate some dose,
since, if it is not possible to obtain a method that converges almost surely in all circumstances
(Theorem 1.1), it is nonetheless natural to want to construct an estimator, on the basis of
observations, that is strongly consistent. As soon as a dose belongs to

D̃,

it becomes possible

to reliably estimate its associated toxicity and the MTD belongs to the set

{a, b},

which is

the minimal set on which we need to have observation when the goal is that of determinating
almost surely the MTD.

Theorem 3.1. Under the Assumptions 2.1 and 3.1, SPM is -sensitive and -balanced (see
remark 1).
Proof.

The proof is given in the supplementary material.

Remark 1. In this theorem, and its proof, we consider that there exists no dose j0 such that
βj0 equals α ± , with  > 0. This assumption is made for the purpose of clarity in presenting
the results.
Large sample behavior of SPM is established by Theorem 3.1. In the case where

E(I , β)

is

non empty, the sequence of doses selected by SPM converges almost surely to one or more
elements belonging to

E(I , β).

In the case where

E(I , β)

is empty, the running estimate of

SPM oscillates between those doses either side of the indierence interval. The two asymptotic
properties of SPM are simultaneously complementary and antagonistic, since, whenever we
diminish the size of the interval
is

-balanced

I ,

we increase the set of circumstances where the method

and we diminish the ones where it is

-sensitive.

Furthermore, the interval

I

can be chosen as small as we wish without having an eect on overall performance of the
method. In the case of the simple parametrisation SPM(0, 1/10, 1/3, 40) presented in section
2.3,



is zero, which aside from the case where a toxicity would equal

α

leads necessarily to

an oscillation. This oscillation, giving an approximation of the two toxicities, allows for us to
construct convergent estimators in all of the scenarios

β:

θ̃n = arg min |α − βbj,n | ,

(9)

j∈D̂n
where

D̂n

is the set of the last two selected doses:

D̂n = {θbn , θbn0 } ,

with

n0 = max{j < n :

θbj 6= θbn } .

Corollary 3.1. Under the Assumptions 2.1 and 3.1, with
almost surely to the MTD.
Proof.

In the case where

D̃ = {a, b} .

 = 0,

the SPM is

-balanced,

 = 0,

the estimator θ̃n converges

which amounts to saying that:

D̂n →

The law of large numbers (Lemma1.1) leads to an immediate result.
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Strong consistency of the estimator based on isotonic regression of the observations could be
obtained in the same way. According to the impossibility theorem of Azriel et al. (2011), the
estimators which possess the property of strong consistency can not be the current estimator
given by the method.

The consistency of these estimators, regardless of the scenario, is

a

possible because the adjacent doses

na → ∞

estimator:

and

nb → ∞.

and

b

will be chosen innitely often by the running

In the case of a nite sample size, experimentation will be

spread over two doses and may give the impression of convergence if the observations on one
dose are close enough to the expected rate. The following corollary considers an asymptotic
characterization of the number of observations allocated to the dose
allocated to

P

and

Q,

b.

relative to the number

For this it is helpful to recall entropy and divergence.

p

are denoted by their parameters

H(q|p) = −p log(q) − (1 − p) log(1 − q) ,
entropy of

a

P : H(p) = H(p|p).

with

and

q.

The entropy of

log 0 = −∞

et

Two Bernoulli laws

Q

relative to

0 × (−∞) = 0

The divergence of Kullbac-Leibler of

P

p ∈ [0, 1],

[p, 1]

the function

and its minimum in

p

DKL (p||.)

is strictly decreasing on

is equal to

[0, p]

is:

; we denote the

relative to

Q

is:

p
1−p
DKL (p||q) = H(q|p) − H(p) = p log( ) + (1 − p) log(
).
q
1−q
For

P

(10)

and strictly increasing on

0.

Corollary 3.2. Under the Assumptions 2.1 and 3.1, when  = 0 and when at least one of the
toxicities βa and βb is dierent from α, we have:
na
DKL (βb ||α)
−→
, a.s.
n→+∞
nb
DKL (βa ||α)

Proof.

The proof is given in the supplementary material.

In situations more general than those for well specied models, the Kullback-Leibler divergence is often used as an appropriate distance measure between two probability laws. This
pseudo-distance is the natural tool to use when showing consistency for Bayesian or maximum
likelihood estimators. In this way, the running estimate for SPM oscillates between doses
and

b

a

according to an asymptotic ratio that is inversely proportional to the pseudo-distance

of Kullback-Leibler between
between

βa

and

βa

and

βb

at the chosen target: the greater the pseudo-distance

α relative to that between βb

and

α the more SPM will recommend the dose b

(and vice versa). The purpose of the following section is to highlight the practical performance
of the usual SPM through a comparison with the CRM.

4

Simulations

The CRM demonstrates good performance with respect to the following criteria:

(PCS),

the percentage of correct selection at the nal recommendation and (TR), the percentage of
patients treated at the MTD. Here, we show that, if we so wish, the prior model of SPM can be
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calibrated in such a way as to reproduce this same performance across many scenarios. This
particular parametrisation is called SP-CRM. The simulations are carried out under a common
situation (α

= 0.2,

power model) where the CRM is considered as close to optimal under an

adaptative minimum-variance criterion (Tian, 2016, Theorem 1 and its interpretation).

Calibration
The target rate is xed at 0.20. The goal is to locate the MTD as one of 6 available doses.
There are 25 patients in each study. We make use of two stage CRM (O'Quigley and Shen,
1996) based on some lead-in rule until we observe the rst toxicity and then we use maximum likelihood.

As proposed by Cheung (dfcrm documentation in the CRAN package),

the chosen skeleton is

u = (0.05, 0.10, 0.20, 0.35, 0.50, 0.70)

with Normal law for the prior

N (0, 1.342 ) together with the power model. Each cohort is of size one meaning that we estimate the dose after each patient.
allowed.

( =

We include the classical restriction that no skipping is

For SP-CRM, the prior model veries 2.1 and Equation (7).

0.015, (q θ )

θ∈D , c

as in Figure 2 a).

=

It is summarized by

48). The modes (q θ )θ∈D are chosen close to the model of the CRM,

They are given by Table 1.

The law

Π

can be used as an alternative

Table 1: The modes of the prior model

qjθ

q.1

q.2

q.3

q.4

q.5

q.6

q1·
q2·
q3·
q4·
q5·
q6·

0.20

0.12

0.02

0.01

0.00

0.00

0.29

0.20

0.07

0.05

0.00

0.00

0.42

0.36

0.20

0.08

0.02

0.00

0.57

0.48

0.35

0.20

0.09

0.01

0.69

0.62

0.50

0.34

0.20

0.04

0.82

0.78

0.70

0.58

0.44

0.20

way to reproduce any initial dose escalation and we are able to choose it so that the method
follows naturally a given increasing sequence of doses until we observe the rst toxicity. An
increasing sequence is denoted
being xed, we dene
rst observed toxicity:

B(s)

s = (s1 , . . . , sk )

sk ∈ D .

with

s

until the

B(s) = {Π : Yj = 0, 1 6 j 6 k ⇒ Xj = sk , 1 6 j 6 k }.

The law

the set of distributions

Π

The modes and the dispersion

that produce the sequence

Ps is the one minimizing the distance in the sense L2 between the uniform distribution
the closure of the convex set
belong to

B(s),

B(s): Ps = arg min||Π − U||2 ,

but there exist distributions in

B(s)

for

Π ∈ B(s).

arbitrarily close to

Ps .

U

and

This law does not
It is then possible

to nd an approximation as accurate as we wish of the least informative distribution belonging
to the closure of the set of measure providing the sequence (R codes available on request).
Table 2 provides such distributions accurate to

10−3

for dierent sequences. These laws are

not normalized but this does not impact the posterior
distribution corresponding to the sequence

d

Πn .

In the following simulations, the

is used. The CRM also produces this sequence

while awaiting to observe the rst toxicity.
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Table 2: Prior

Π,

walk through the levels awaiting the rst observed toxicity.

Π(1)

Π(2)

Π(3)

Π(4)

Π(5)

Π(6)

a: 111222333444555666

1

0.832

0.482

0.346

0.194

0.103

b: 112233445566******

1

0.913

0.663

0.554

0.392

0.272

c: 123456************

1

0.999

0.910

0.883

0.787

0.709

d: 1234556***********

1

0.999

0.910

0.883

0.787

0.604

3
1

2

Doses

4

5

Sequences without toxicity

5

10

15

20

25

Patients

Figure 3: An example of a sequence for SP-CRM,
toxicity,

×:

β = (0.01, 0.07, 0.10, 0.20, 0.40, 0.70); 4:

non-toxicity.

Model and prior model
Table 3 shows performance of SP-CRM when compared to the CRM according to the criteria
(PCS) and (TR) for 10 000 replications. The ndings show very similar behavior for the rst
4 scenarios. When the data are generated exactly by the model being used for CRM (scenario
3), rather surprisingly, that does not appear to grant any advantage to the method and the SPCRM appears to suer no handicap as a price to pay for the extra-exibility and adaptability
of its prior model. On the other hand, scenario 4 presents an interesting illustration in which
the CRM fails to satisfy the Assumption 1.3 and, as a result, does not possess the property
of convergence to the MTD. Despite this, for a trial of 25 patients, it is dicult to observe
any theoretical advantage of SP-CRM over CRM. However, it is enough to slowly increase
sample size to observe this convergence diculty manifesting itself in practice (see gure 4).
Increasing the number of patients included in the study fails to lead to improvement for
CRM. In contrast, the SP-CRM is

-sensitive

corresponds to almost sure convergence.

and the portion of the curve that is traced out

In a real practical sense, as sample size increases,

SP-CRM does better and better. In some ways, for CRM we were fortunate in that the best
performance was already obtained around 25 subjects and increasing this number was not
rewarded by increased accuracy. Beyond that sample size the handicap begins to show itself.
In other scenarios, for instance 5 and 6, where the model specication is yet more severely
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Table 3: Some varied scenarios.
Doses

1

Scenario 1
PCS

TR

SP-CRM
CRM
SP-CRM
CRM

TR

TR

TR

TR

TR

0.26

0.28

0.3

0.35

0.50

21.5

13.2

9.6

5.4

0.6

19.5

14.3

11.2

6.0

0.6

20.6

13.5

9.1

7.0

2.1

17.6

14.1

10.7

7.6

2.2

0.35

0.50

0.70

19.7

01.2

0.0

20.2

01.3

0.0

19.0

05.9

00.7

20.4

06.4

00.8

22.7

CRM

02.4

22.2

SP-CRM

10.8

24.3

CRM

12.3

22.1

0.20
54.0
53.9
39.0
37.7

4.9

5.3

9.7

20.7

0.18
59.2
58.4
40.7
40.1

0.01

0.02

0.05

0.11

0.14

SP-CRM

0.0

0.1

3.2

15.7

31.0

0.01

0.02

0.05

0.09

SP-CRM

0.0

0.2

2.8

20.3

CRM

0.0

0.1

3.4

21.8

SP-CRM

4.6

6.0

10.5

19.9

CRM

0.40
17.3
16.1
17.9
19.0

CRM

0.0

0.1

3.4

15.5

31.2

SP-CRM

4.6

5.8

10.8

16.7

26.7

CRM

4.9

5.3

10.2

16.7

25.9

0.0

0.0

0.3

0.35

0.4

SP-CRM

0.0

2.3

31.5

11.1

3.2

CRM

0.0

3.5

33.6

12.6

3.6

SP-CRM

4.0

11.8

24.3

13.7

5.8

CRM

4.7

11.0

0.16
51.7
46.7
40.3
36.3

0.21
49.8
49.6
35.1
36.0

26.7

14.5

6.5

0.0

0.0

0.0

0.3

0.35

SP-CRM

0.0

0.0

10.2

CRM

0.0

0.0

10.5

SP-CRM

4.0

4.0

19

CRM

4.0

4.0

16.9

Scenario 6
PCS

6

0.10

Scenario 5
PCS

5

2.3

Scenario 4
PCS

4

0.05

Scenario 3
PCS

3

SP-CRM

Scenario 2
PCS

0.20
49.4
48.1
47.4
47.6

2

0.23
56.8
52.3
38.8
37.8

23.6

9.2

26.9

10.2

22.8

11.1

24.4

12.7

tested and struggles to accommodate a slope in the neighbourhood of the MTD that is a
strain to t, SP-CRM shows clearly superior performance, both as measured by PCS and as
measured by TR. The SP-CRM gains its advantage from the exibility of the prior model that
can readjust to each observation. The same argument underlies its asymptotic performance
and its adaptability to those situations that appear far removed from the model. In order to
conrm this impression, we randomly generated scenarios by making use of order statistics
of quasi-uniform variates (see gure 5). For this purpose the following algorithm, called

pseudo-uniform scenario

is used.

 The MTD is selected uniformly from a range of doses
value

the

D: M T D ∼ UD

; resulting in the

k.
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Figure 4: For scenario 6, (PCS) as a function of the number of included patients in the study.

:

SP-CRM ;

×:

CRM.

Bs = α + (1 − α) × M

M

is a random variable

having a Beta law depending on the MTD and the number of doses

m: M ∼ B(max{m−

 We randomly select an upper bound

;

k; 0.5}, 1).
β

 The random scenario

has the law of an ordered sample of

uniform laws on

[0, Bs ]

0.8
0.6
Toxicity
0.4
0.2
0.0

0.0

0.2

0.4

Toxicity

0.6

0.8

1.0

{M T D = k}.

1.0

conditioned by the event

m

1

2

3

4

5

6

1

2

3

Doses

4

5

6

Doses

(a) Sample under the pseudo-uniform algorithm

(b) Sample under Λ

Figure 5: Scenarios tested and scenarios generated by the prior.
The second point downweights the importance of the more extreme scenarios in which the
toxic probabilities following the MTD rise very sharply. Such scenarios can still be sampled
but less frequently. Sampling of the law
MTD is located at level 2,

Bs

M

is natural; indeed when we have 6 doses and the

is the maximum of 4 uniform laws on

[α, 1].

Table 4 compares

the performance of the CRM and its semi-parameteric version over the set of 100 000 randomly
generated scenarios. Three additional criteria enabling comparison are introduced. (TR(a, b))
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is the percentage of patients treated at doses

a

and

b

(see the denition 3.2); (∆) is the mean

of the dierence between the toxic rates at which patients are treated and the toxicity at the
MTD. The fth criteria (R-∆) is an index based on the statistic (∆) relative to that value
obtained by the optimal design (O'Quigley et al., 2002). The optimal design is based on the
idea of complete and incomplete information.

We can use it sequentially, in a theoretical

setting, to provide a running best estimate of the MTD, the level at which we would like
to treat the next included patient in the study. In order to maintain comparability, at least
early on, we constrain the optimal design to similar behaviour such as that imposed on the
CRM, i.e., only increases in level by one level at a time. This helps provide a reference for the
criterion (∆) :

∆(Opt) = 9.75.

The base reference is calculated for the CRM.

R-∆(M)

As R-∆ gets closer to

0,

=

∆(M) − ∆(OPT)
∆(CRM) − ∆(OPT)

(11)

all the more the considered method gets close to the optimal design.

In all categories, the SP-CRM obtains the best results (Table 4). Regarding the criteria (∆),

Table 4: Comparison from a sample scenario (size=100 000).
Criterion

PCS

TR

TR(a,b)

∆

R-∆

CRM

50.43

39.23

59.68

10.05

1.0

SP-CRM

51.45

39.56

60.22

9.93

0.6

SPM(0, 1/10, 1/3, 40)

51.16

39.19

59.80

10.12

1.23

the dierence between the SP-CRM and the optimal method is 40% smaller than that which
obtains when comparing the CRM to the optimal.

This signicant gain can be explained

in part by the fact that we are very close to the performance of the optimal method.

The

parametrisation SPM(0, 1/10, 1/3, 40) from Section 2.2 obtains good results, even if its
distance to the optimal method looks slightly greater than that for the CRM. This leads us to
conclude that very simple parametrisations of SP-CRM can attain comparable performance
to those of the CRM, even in cases where the CRM is considered to be near optimal (Tian,
2016).
In these simulations, it is important to keep in mind that our goal was to emulate as best we
could the behaviour of the CRM. Since this can be accomplished we can conclude that we do no
worse than the CRM. However, the greater exibility allows us to do better in those particular
cases that prove thorny for the CRM since the explanation for the awkward behaviour here
is the strong parametrisation of the CRM, a feature that is greatly relaxed in SP-CRM. It
remain to study the great range of SPM parametrisation under dierent circumstances. The
posterior

Πn

on the doses suggests some avenues of exploration for estimating the MTD by

groups of doses which may show itself to be of value when we move beyond Phase I to the
Phase I/II setting.
and

4.

In Figure 6 , the target is

α = 0.2

At the end of the trial the posterior puts

81%

and the MTD is located between

3

of its mass over these two doses. In
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(a) The trial, 4 =toxic, × =non-toxic.
Figure 6: A balanced scenario:

(b) The nal posterior Π.

β = (0.04, 0.08, 0.16, 0.24, 0.35, 0.45).

this article we have not presented any results concerning SPM and methods other than the
CRM. Such comparisons can be readily carried out both in theory and in practice leading to
improvements on methods currently in use. We study this more deeply in a separate paper.

Conclusion and perspectives
The central feature of the SPM is the direct modelling of the key parameter of interest, the
dose itself, structured around a regression function that is not fully specied. The approach
is expressed via a hierarchical Bayesian structure. So far, we have not tried to increase the
exibility of the usual prior as a way to better deal with poor model specication. Instead
we replace the model by a prior that we call the prior model. The topological support of this
is indexed by the parameter of main interest, the MTD. From the asymptotic standpoint, we
no longer seek to obtain convergence on the set of posterior laws, but only on the particular
law surrounding the parameter of interest, the MTD. This, albeit small, change in emphasis
leads to improved asymptotic behaviour. In particular we obtain the almost sure convergence
of the estimator of the MTD built on the observations obtained by the method.
As a by-product we obtain much more and we note that the generalization is suciently
exible to allow it to include almost all of the currently used model-based designs as special
cases.

Here we have applied the generalization to the specic case of the CRM which is a

strongly parametrized method.

We are currently working on doing the same thing for the

CCD, the mTPI and the BOIN methods, all of which can be seen to be less parametric since
they do not explicitly model the relation

Y ≈ f (X).

All of these methods achieve good

performance both in the treatment of patients and in the accurate locating of the MTD.
Being able to put them under a single umbrella - semi-parametric dose nding methods - will
enable us to better study the dierences and the similarities between them and, ultimately,
to construct improvements. The SPM framework allows for theoretical study, the results of
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which will then apply to all of these special cases. Furthermore, the SPM can be used in its
own right as a method, as it stands, and our theoretical and simulation based investigations
suggest that it is at least as good, and in most cases better, than all the methods we have
already tested.
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